Following the publication of the Review article by Jean W Lee & Marian Kelley entitled ‘Quality assessment of bioanalytical quantification of monoclonal antibody drugs‘, in the March 2011 issue of Therapeutic Delivery (Therapeutic Delivery 2[3], 383–396 [2011]), it has been brought to our attention that:
Under the section ‘Sample dilution & minimum-required dilution‘ the sentence states:
“Therefore, bioanalysts employing LC–MS methods are unable to follow the FDA guidance, which states that the concentrations of standard calibrators are chosen on the basis of the concentration range expected in a particular study [105].”
This should have read:
“Therefore, bioanalysts employing LBA methods are unable to follow the FDA guidance, which states that the concentrations of standard calibrators are chosen on the basis of the concentration range expected in a particular study [105].”
The authors and editors of Therapeutic Delivery would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.